U.S. health regulator authorizes Sobi’s COVID drug


Nov 10 (Reuters) – Sobi North America, the North American unit of Swedish Orphan Biovitrum AB , said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug, Kineret, for treating COVID-19 related pneumonia.

Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.



Source link

Ozinize
Logo
Shopping cart